Biosimilars for Rheumatoid Arthritis Riding the 2023 Wave

Dr Stanley Cohen, the Department of Internal Medicine, University of Texas Southwestern Medical Center, and Mariah Z. Leach, Mamas Facing Forward, Colorado, discuss some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The podcast also covers the difference between a generic medicine and a biosimilar, and the clinical evidence to support the safety and efficacy of adalimumab biosimilars in patients with rheumatoid arthritis.

This podcast is intended for health care professionals and patients with the aim of discussing some of the concerns that patients may have about initiating treatment with a biosimilar, or switching from their current medication to a biosimilar, for Rheumatoid Arthritis. The podcast also covers the definitions of a biosimilar, interchangeable biosimilar, and switching, before discussing the available data supporting the efficacy and safety of biosimilars in Rheumatoid Arthritis.

The authors of this podcast include Stanley Cohen, MD, Professor at University of Texas Southwestern Dallas, TX, and Mariah Z. Leach, who is a patient advocate and the founder of Mamas Facing Forward in Louisville, Colorado. This podcast has not been peer-reviewed but has been vetted by the journal’s Editor-in-Chief.  Content and technical support were provided by Envision Pharma Group, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI). for these services. BIPI was given the opportunity to review earlier talking points and the final transcript for medical and scientific accuracy, as well as intellectual property considerations. Copyright © 2023, Boehringer Ingelheim Pharmaceuticals, Inc.. All rights reserved.